- Home
- RECT vs CRDL Comparison
RECT vs CRDL Comparison
Compare RECT & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RECT
- CRDL
- Stock Information
- Founded
- RECT 1997
- CRDL 2017
- Country
- RECT Singapore
- CRDL Canada
- Employees
- RECT N/A
- CRDL N/A
- Industry
- RECT
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RECT
- CRDL Health Care
- Exchange
- RECT Nasdaq
- CRDL Nasdaq
- Market Cap
- RECT 88.2M
- CRDL 102.0M
- IPO Year
- RECT 2024
- CRDL N/A
- Fundamental
- Price
- RECT $3.91
- CRDL $1.20
- Analyst Decision
- RECT
- CRDL Strong Buy
- Analyst Count
- RECT 0
- CRDL 3
- Target Price
- RECT N/A
- CRDL $9.00
- AVG Volume (30 Days)
- RECT 5.9K
- CRDL 274.8K
- Earning Date
- RECT 03-07-2025
- CRDL 03-31-2025
- Dividend Yield
- RECT N/A
- CRDL N/A
- EPS Growth
- RECT N/A
- CRDL N/A
- EPS
- RECT 0.20
- CRDL N/A
- Revenue
- RECT $30,673,388.00
- CRDL N/A
- Revenue This Year
- RECT N/A
- CRDL N/A
- Revenue Next Year
- RECT N/A
- CRDL N/A
- P/E Ratio
- RECT $19.64
- CRDL N/A
- Revenue Growth
- RECT 9.86
- CRDL N/A
- 52 Week Low
- RECT $2.70
- CRDL $1.15
- 52 Week High
- RECT $7.68
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- RECT N/A
- CRDL 41.60
- Support Level
- RECT N/A
- CRDL $1.15
- Resistance Level
- RECT N/A
- CRDL $1.51
- Average True Range (ATR)
- RECT 0.00
- CRDL 0.10
- MACD
- RECT 0.00
- CRDL -0.01
- Stochastic Oscillator
- RECT 0.00
- CRDL 13.65
About RECT Rectitude Holdings Ltd Ordinary Shares
Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.